SHORT COMMUNICATION

Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75

Colin Rae¹ | John W. Babich² | Robert J. Mairs¹

¹ Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK
² Department of Radiology, Cornell University, Ithaca, New York, USA

Correspondence
Colin Rae, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1BD, Scotland, UK.
Email: colin.rae@glasgow.ac.uk

Abstract
The elevated activity of fatty acid synthase has been reported in a number of cancer types. Inhibition of this enzyme has been demonstrated to induce cancer cell death and reduce tumor growth. In addition, the fatty acid synthase inhibitor drug C75 has been reported to synergistically enhance the cancer-killing ability of ionizing radiation. However, clinical use of C75 has been limited due to its producing weight loss, believed to be caused by alterations in the activity of carnitine palmitoyltransferase-1. C75 is administered in the form of a racemic mixture of (−) and (+) enantiomers that may differ in their regulation of fatty acid synthase and carnitine palmitoyltransferase-1. Therefore, we assessed the relative cancer-killing potency of different enantiomeric forms of C75 in prostate cancer cells. These results suggest that (−)-C75 is the more cytotoxic enantiomer and has greater radiosensitizing capacity than (+)-C75. These observations will stimulate the development of fatty acid synthase inhibitors that are selective for cancer cells and enhance the tumor-killing activity of ionizing radiation, while minimizing weight loss in cancer patients.

KEYWORDS
C75, fatty acid synthase, ionizing radiation

1 | INTRODUCTION

Fatty acid synthase (FASN) is the enzyme responsible for endogenous synthesis of saturated long-chain fatty acids from the precursors acetyl-CoA and malonyl-CoA. Many common human cancers, including carcinoma of the prostate and breast, express high levels of FASN compared with normal human tissues.¹⁻³ This elevated expression is associated with protection against apoptosis, increased metastasis, and poor prognosis. Inhibitors of FASN decrease prostate cancer cell proliferation, increase apoptosis, and decrease tumor growth in experimental models. The natural fungal product cerulenin is an inhibitor of FASN and a US Food and Drug Administration (FDA)-approved antiobesity drug. Synthetic derivatives such as the competitive irreversible FASN inhibitor C75 are more chemically stable.

Inhibition of FASN by C75 induced apoptosis in cancer cells. This was probably caused by elevated levels of the FASN substrate malonyl-CoA.⁴ Malonyl-CoA also inhibits carnitine palmitoyltransferase (CPT-1), the rate-limiting enzyme of fatty acid oxidation, preventing the oxidation of newly synthesized fatty acids.⁵ CPT-1 stimulation by C75, however, does not appear to play a role in the cytotoxic response.⁵

We have previously demonstrated that C75 was cytotoxic to prostate cancer cell lines (PC3 and LNCaP), decreased...
survival of PC3 clonogens, and inhibited the growth of multicellular spheroids composed of LNCaP cells. Crucially, C75 enhanced the clonogenic kill and spheroid growth delay induced by experimental radiotherapy in a synergistic manner characteristic of a radiosensitizer.

Although C75 exhibits selective killing of cancer cells, its side effects of anorexia and weight loss have limited its potential for the treatment of cancer patients. C75-induced modulation of CPT-1 appears to be responsible for its capacity to reduce weight. However, the mechanism of action is unresolved. C75 directly activates CPT-1, leading to increased fatty acid β-oxidation with consequent weight loss. Conversely, experiments in vitro and in rodent models demonstrated that C75 is converted to C75-CoA. Accumulation of C75-CoA and malonyl-CoA, caused by reduced FASN activity, act as signals of nutrient abundance to hypothalamic neurons, inhibiting CPT-1 and mediating the suppression of food intake and further contributing to weight loss. This has led to the evaluation of drugs that inhibit FASN but do not affect CPT-1 activity.

Mims et al. recently demonstrated that inhibition of FASN sensitized cancer cells to experimental radiation therapy. However, that study used orlistat, which is poorly soluble and has an extremely low oral bioavailability, thus limiting its clinical application. Radiosensitization of cancer cells was also achievable using C75. However, it is possible that the racemic mixture of C75 may modulate the activity of CPT-1, which is responsible for its undesirable effects on body weight and appetite in patients with cancer. Here we evaluated the radiosensitizing activity of enantiomers of C75 in comparison with the commonly used racemic mixture of C75.

**Materials and Methods**

Human prostate cancer cell lines PC3 and LNCaP were obtained from the American Type Culture Collection (Manassas, VA) and were used in this study for less than 6 months after resuscitation. Cell lines were maintained as previously described. Racemic mixtures of C75 were purchased from Sigma-Aldrich (Dorset, UK) and Santa Cruz Biotechnology (Santa Cruz, CA). Enantiomers of C75 [(-)-trans-C75 and (+)-trans-C75] were purchased from Santa Cruz Biotechnology. The structure of the enantiomers of C75 is shown in Figure 1. A methyl tetrazolium (MTT) cytotoxicity assay was performed on cell lines in 96-well plates after administration of drugs for 24 h. For clonogenic assay, PC3 cells in exponential growth phase were treated with drugs alone or in simultaneous combination with radiation using an X-Strahl RS225 X-ray irradiator at a dose rate of 1.6 Gy per min. After 24 h treatment, cells were seeded for clonogenic survival assay. Cells were incubated at 37°C in 5% CO₂ for 10 days. Colonies were fixed in methanol, stained with crystal violet solution, and colonies of at least 50 cells were counted. Data are presented as means ± standard error of the mean (SEM) of three separate experiments. Statistical significance was determined using

![FIGURE 1](image1.png)

**FIGURE 1** Structure of the enantiomers of C75.

![FIGURE 2](image2.png)

**FIGURE 2** Cytotoxicity of different stereoisomers of C75. MTT assay of A, PC3 and B, LNCaP cells in response to racemic mixtures of C75 (+/-) from two commercial sources (Sigma-Aldrich and Santa Cruz Biotechnology), or (-) and (+) enantiomers of C75 from Santa Cruz Biotechnology.

![FIGURE 3](image3.png)

**FIGURE 3** Clonogenic survival of PC3 prostate cancer cells in response to racemic mixtures and enantiomers of C75.
Student's t-test. \( P < 0.05 \) was considered statistically significant and \( <0.01 \) highly significant.

3 | RESULTS AND DISCUSSION

The potency of C75, obtained from Sigma-Aldrich and used in previous studies, was compared with a racemic mixture and enantiomers purchased from Santa Cruz Biotechnology. The two racemic mixtures had almost identical cytotoxic potency in both cell lines (Figure 2). However, the \((-)\) enantiomer was more potent than the racemic mixture, whereas the \((+1)\) enantiomer had less potency than the racemic mixture in both cell lines. This is in agreement with the antitumor effect of C75 previously described by Makowski et al.\(^{11}\) in breast and ovarian cancer cell lines, wherein the \((+1)\) enantiomer of C75 was less potent than the racemic mixture or the \((-)\) enantiomer. Similar to the cytotoxicity assays, in clonogenic assays of PC3 cells the racemic mixtures had near identical activity, which was less than the \((-)\) enantiomer and more than the \((+1)\) enantiomer (Figure 3). In clonogenic assays, the 50% clonogenic kill (IC\(_{50}\)) values were 37.01 \(\pm\) 1.45 and 37.81 \(\pm\) 1.23 \(\mu\text{M}\) for Sigma-Aldrich and Santa Cruz C75, respectively. The \((-)\) enantiomer of C75 had significantly greater clonogenic killing potency (IC\(_{50}\) 28.08 \(\pm\) 0.66 \(\mu\text{M}\)) than the racemic mixture, whereas the \((+1)\) enantiomer of C75 had substantially less effect, reflected in an IC\(_{50}\) value of 51.36 \(\pm\) 7.67 \(\mu\text{M}\).

For the first time, the radiosensitizing activity of C75 enantiomers was also evaluated. Greater than additive enhancement of radiation-induced clonogenic kill was observed with the racemic mixture of C75 or the \((-)\) enantiomer when administered at 25 \(\mu\text{M}\) (Figure 4). In contrast, \((+1)\)-C75 did not induce a significant enhancement of radiation-induced clonogenic kill. Crucially, the radiosensitizing activity of \((-)\)-C75 was evident even when administered at 10 \(\mu\text{M}\)—a concentration that does not induce significant clonogenic cell kill (Figure 2a).

It has previously been reported that, although C75 had a minimal effect on CPT-1 activity, \((+1)\)-C75-CoA inhibited CPT-1 to a significantly greater extent than either racemic C75-CoA or \((-)\)-C75-CoA.\(^{11}\) Furthermore, when injected into rats the anorectic effect of C75 was largely attributed to the presence of \((-)\)-C75.\(^{11}\) These findings, combined with the observations that \((-)\)-C75 was able to inhibit FASN activity and was cytotoxic to cancer cell lines, suggested that \((-)\)-C75 is likely to display the beneficial antitumor effects in the absence of significant side effects associated with the racemic C75. Therefore, we assessed the radiopotentiation of the stereoisomers of C75 in vitro and observed that the radiosensitizing activity was a property only of the \((-)\)-C75 enantiomer. Importantly, the clonogenic killing potency of \((-)\)-C75 was greater than either racemic C75 or \((+1)\)-C75. It is expected that clinical application of the \((-)\) enantiomer of C75 will improve the treatment of metastatic prostatic carcinoma without inducing adverse anorexia. This combination of \((-)\)-C75 with radiotherapy is also likely to be effective in other tumor types that overexpress fatty acid synthase.

4 | CONCLUSION

We demonstrate here that the antitumor potential and radiosensitizing activity of C75 is due to the \((-)\)-C75 enantiomer. It is expected that therapeutic use of this enantiomer will reduce the previously limiting clinical effect of weight loss in cancer patients.

ACKNOWLEDGMENTS

This work was supported by a grant from Prostate Cancer UK (PG12–12).

REFERENCES

1. Shurbaji MS, Kuhajda FP, Pasternack GR, Thurmond TS. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathol. 1992;97:686–691.

2. Epstein JL, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology. 1995;45:81–86.
3. Pizer ES, Pflog BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. *Prostate*. 2001;47:102–110.

4. Pizer ES, Thupari J, Han WF, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. *Cancer Res*. 2000;60:213–218.

5. Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. *Cancer Res*. 2003;63:7330–7337.

6. Rae C, Haberkorn U, Babich JW, Mairs RJ. Inhibition of fatty acid synthase sensitizes prostate cancer cells to radiotherapy. *Radiat Res*. 2015;184:482–493.

7. Thupari JN, Kim EK, Moran TH, Ronnett GV, Kuhajda FP. Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. *Am J Physiol Endocrinol Metab*. 2004;287:E97–E104.

8. Aja S, Landree LE, Kleman AM, et al. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. *Am J Physiol Regul Integr Comp Physiol*. 2008;294:R352–R361.

9. Bentebibel A, Sebastián D, Herrero L, et al. Novel effect of C75 on carnitine palmitoyltransferase 1 activity and palmitate oxidation. *Biochemistry*. 2006;45:4339–4350.

10. Mera P, Bentebibel A, López-Viñas E, et al. C75 is converted to C75-CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase 1 and decreases food intake and body weight. *Biochem Pharmacol*. 2009;77:1084–1095.

11. Makowski K, Mera P, Paredes D, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (−)-C75 has antitumor activity. *Chirality*. 2013;25:281–287.

12. Sadowski MC, Pouwer RH, Gunter JH, Lubik AA, Quinn RJ, Nelson CC. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. *Oncotarget*. 2014;5:9362–9381.

13. Relat J, Blancafort A, Oliveras G, et al. Different fatty acid metabolism effects of (−)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. *BMC Cancer*. 2012;12:280.

14. Mims J, Bansal N, Bharadwaj MS, et al. Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer. *Radiat Res*. 2015;183:291–304.

15. McNeely W, Benfield P. Orlistat. *Drugs*. 1998;56:241–249.

**How to cite this article:** Rae C, Babich JW, Mairs RJ. Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75. *Chirality* 2017;29:10–13. doi: 10.1002/chir.22668